Patents by Inventor Tae Hyeon Yoo
Tae Hyeon Yoo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11998612Abstract: An antibody conjugating peptide including an amino acid having a photoreactive functional group, a physiologically active substance modified with the conjugating peptide, and an antibody conjugate having an antibody linked to the physiologically active substance are disclosed. When the physiologically active substance modified with the conjugating peptide is linked to the antibody, the conjugation efficiency between the antibody and the physiologically active substance is remarkably improved as compared to that of the conventional art, and thus, the drug may be firmly bound without impairing the specificity of the antibody, thereby making it possible to accelerate commercialization of the antibody conjugate.Type: GrantFiled: June 21, 2023Date of Patent: June 4, 2024Assignee: NOVELTY NOBILITY INC.Inventors: Tae Hyeon Yoo, Jisoo Park, Yumi Lee
-
Publication number: 20240151714Abstract: The present invention relates to a target analyte detection composition based on a proximity proteolysis reaction and a target analyte detection method using same. More specifically, the present invention relates to a method for detecting a target analyte, the method comprising a step in which when a first binder and a second binder bind to the target analyte, hybridization is made between ssDNA linked to the first binder and ssDNA linked to a protease and between ssDNA linked to the second binder and ssDNA linked to a zymogen, whereby a signal generated by a proximity proteolysis reaction between the protease and the zymogen is detected.Type: ApplicationFiled: March 14, 2022Publication date: May 9, 2024Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Tae Hyeon YOO, Hyeon Ji PARK
-
Publication number: 20240016947Abstract: An antibody conjugating peptide including an amino acid having a photoreactive functional group, a physiologically active substance modified with the conjugating peptide, and an antibody conjugate having an antibody linked to the physiologically active substance are disclosed. When the physiologically active substance modified with the conjugating peptide is linked to the antibody, the conjugation efficiency between the antibody and the physiologically active substance is remarkably improved as compared to that of the conventional art, and thus, the drug may be firmly bound without impairing the specificity of the antibody, thereby making it possible to accelerate commercialization of the antibody conjugate.Type: ApplicationFiled: June 21, 2023Publication date: January 18, 2024Applicant: NOVELTY NOBILITY INC.Inventors: Tae Hyeon YOO, Jisoo PARK, Yumi Lee
-
Patent number: 11723984Abstract: The present invention relates to an antibody conjugating peptide including an amino acid having a photoreactive functional group, a physiologically active substance modified with the conjugating peptide, and an antibody conjugate having an antibody linked to the physiologically active substance. When the physiologically active substance modified with the conjugating peptide according to the present invention is linked to the antibody, the conjugation efficiency between the antibody and the physiologically active substance is remarkably improved as compared to that of the conventional art, and thus, the drug may be firmly bound without impairing the specificity of the antibody, thereby making it possible to accelerate commercialization of the antibody conjugate.Type: GrantFiled: November 29, 2018Date of Patent: August 15, 2023Assignee: NOVELTY NOBILITY INC.Inventors: Tae Hyeon Yoo, Jisoo Park, Yumi Lee
-
Patent number: 11519918Abstract: The present invention relates to a method for quantification of amino acids using a cell-free protein synthesis system.Type: GrantFiled: July 24, 2018Date of Patent: December 6, 2022Assignee: THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC)Inventors: Dong-Myung Kim, Tae Hyeon Yoo, Kyung-Ho Lee, Yeon-Jae Jang
-
Publication number: 20210348219Abstract: A method for detecting a target nucleic acid includes: (a) a step of mixing a sample containing the target nucleic acid with a nucleic acid detection solution containing i) ssDNA-protease conjugate, ii) ssDNA-zymogen conjugate, and iii) a substrate specific for the zymogen; and (b) a step of detecting a signal generated by a proximity proteolysis reaction between the ssDNA-zymogen conjugate and the ssDNA-protease conjugate which are hybridized to the target nucleic acid.Type: ApplicationFiled: October 2, 2019Publication date: November 11, 2021Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Tae Hyeon YOO, Hyeon Ji PARK
-
Publication number: 20210123929Abstract: The present invention relates to a method for quantification of amino acids using a cell-free protein synthesis system.Type: ApplicationFiled: July 24, 2018Publication date: April 29, 2021Inventors: Dong-Myung KIM, Tae Hyeon YOO, Kyung-Ho LEE, Yeon-Jae JANG
-
Publication number: 20200397912Abstract: The present invention relates to an antibody conjugating peptide including an amino acid having a photoreactive functional group, a physiologically active substance modified with the conjugating peptide, and an antibody conjugate having an antibody linked to the physiologically active substance. When the physiologically active substance modified with the conjugating peptide according to the present invention is linked to the antibody, the conjugation efficiency between the antibody and the physiologically active substance is remarkably improved as compared to that of the conventional art, and thus, the drug may be firmly bound without impairing the specificity of the antibody, thereby making it possible to accelerate commercialization of the antibody conjugate.Type: ApplicationFiled: November 29, 2018Publication date: December 24, 2020Applicant: NOVELTY NOBILITY INC.Inventors: Tae Hyeon YOO, Jisoo PARK, Yumi LEE
-
Patent number: 10435443Abstract: Provided is a peptide that binds to a toll-like receptor 4 (TLR4)/myeloid differentiation factor 2 (MD2) composite and inhibit secretion of interleukin-6 (IL-6), nitrogen monoxide (NO) and reactive oxygen species (ROS), and activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF?B) and mitogen-activated protein kinases (MAPKs) via inhibiting a TLR4 signaling pathway induced by a liphopolysaccharide (LPS); a TLR4 antagonist including the peptide; and a composition thereof for preventing or treating autoimmune diseases and inflammatory diseases.Type: GrantFiled: July 31, 2015Date of Patent: October 8, 2019Assignee: Genesen Co., Ltd.Inventors: Sangdun Choi, Tae Hyeon Yoo, Seol Hee Park
-
Publication number: 20180148487Abstract: The present disclosure relates to a peptide for inhibiting a TLR4 signaling pathway, a TLR4 antagonist including the peptide, and a composition for preventing or treating autoimmune diseases and inflammatory diseases. More specifically, the present disclosure relates to a peptide which binds to a TLR4/MD2 composite to inhibit the secretion of interleukin-6 (IL-6), NO, and ROS, and the activation of NF?B and MAPKs, a TLR4 antagonist including the peptide, and a composition for preventing or treating autoimmune diseases and inflammatory diseases. The peptide according to the present disclosure has an excellent effect of inhibiting the secretion of interleukin-6 (IL-6), NO, and ROS, and the activation of NF?B and MAPKs by inhibiting a TLR4 signaling pathway induced by a liphopolysaccharide (LPS), and thus can be favorably used as a composition for preventing or treating autoimmune diseases and inflammatory diseases occurring by the TLR4 signaling pathway.Type: ApplicationFiled: July 31, 2015Publication date: May 31, 2018Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Sang Dun CHOI, Tae Hyeon YOO, Seol Hee PARK
-
Publication number: 20120148559Abstract: The invention provides deimmunized mutant proteins having reduced immunogenicity while exhibiting substantially the same or greater biological activity as the proteins of interst from which they are derived, as exemplified by mutant L-asparaginase that comprises amino acid substitutions compared to wild type L-asparaginase. The invention further provides methods for screening mutant deimmunized proteins that have substantially the same or greater biological activity as a protein of interest, and methods for reducing immunogenicity, without substantially reducing biological activity, of a protein of interest. The invention's compositions and methods are useful in, for example, therapeutic applications by minimizing adverse immune responses by the host mammalian subjects to the protein of interest.Type: ApplicationFiled: November 30, 2011Publication date: June 14, 2012Applicant: Board of Regents The University of Texas SystemInventors: George Georgiou, Jason Cantor, Tae Hyeon Yoo